Last reviewed · How we verify
IKH-01
IKH-01 is a small molecule that targets the SGLT2 receptor.
IKH-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | IKH-01 |
|---|---|
| Also known as | norethisterone and ethinyl estradiol |
| Sponsor | Nobelpharma |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
IKH-01 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, but the exact molecular details of IKH-01's interaction with the SGLT2 receptor are not well understood.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea (PHASE3)
- Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers (PHASE3)
- Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IKH-01 CI brief — competitive landscape report
- IKH-01 updates RSS · CI watch RSS
- Nobelpharma portfolio CI